It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
The implementation of governmental Non-Pharmaceutical Interventions (NPIs) has been the primary means of controlling the spread of the COVID-19 disease. One of the intended effects of these NPIs has been to reduce population mobility. Due to the huge costs of implementing these NPIs, it is essential to have a good understanding of their efficacy. Using aggregated mobility data per country, released by Apple and Google we investigated the proportional contribution of NPIs to the magnitude and rate of mobility changes at a multi-national level. NPIs with the greatest impact on the magnitude of mobility change were lockdown measures; declaring a state of emergency; closure of businesses and public services and school closures. NPIs with the greatest effect on the rate of mobility change were implementation of lockdown measures and limitation of public gatherings. As confirmed by chi-square and cluster analysis, separately recorded NPIs like school closure and closure of businesses and public services were closely correlated with each other, both in timing and occurrence. This suggests that the observed significant NPI effects are mixed with and amplified by their correlated NPI measures. We observed direct and similar effects of NPIs on both Apple and Google mobility data. In addition, although Apple and Google data were obtained by different methods they were strongly correlated indicating that they are reflecting overall mobility on a country level. The availability of this data provides an opportunity for governments to build timely, uniform and cost-effective mechanisms to monitor COVID-19 or future pandemic countermeasures.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details




1 ClinLine, Leiderdorp, The Netherlands
2 OCS Life Sciences, ‘s Hertogenbosch, The Netherlands
3 The Department of Biostatistics and Health informatics, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, UK (GRID:grid.13097.3c) (ISNI:0000 0001 2322 6764)
4 The Department of Biostatistics and Health informatics, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, UK (GRID:grid.13097.3c) (ISNI:0000 0001 2322 6764); University College London, Institute of Health Informatics, London, UK (GRID:grid.83440.3b) (ISNI:0000000121901201)
5 The Department of Biostatistics and Health informatics, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, UK (GRID:grid.13097.3c) (ISNI:0000 0001 2322 6764); University College London, Institute of Health Informatics, London, UK (GRID:grid.83440.3b) (ISNI:0000000121901201); South London and Maudsley NHS Foundation Trust, London, UK (GRID:grid.37640.36) (ISNI:0000 0000 9439 0839)